Victoza (liraglutide) is a prescription drug used to help manage type 2 diabetes and reduce the risk of certain diabetes-related heart problems. Victoza is given as a daily injection under the skin.

While the number of prescription fills for GLP-1 receptor agonists has continued to increase, health Insurance coverage for ...

Hikma launched liraglutide, a generic version of an earlier Novo Nordisk weight loss drug, in the US in December. Liraglutide, which Novo sells as Victoza for diabetes and Saxenda for weight loss, has ...

Victoza (liraglutide) and Ozempic (semaglutide) are two injectable drugs known as GLP-1 agonists used to treat people with type 2 diabetes. While some GLP-1 agonists are used for weight loss in ...

Novo Nordisk has settled a US patent case with Teva, which prevents the Israel-based generics firm marketing a cheaper version of its key type 2 diabetes drug Victoza until 2023.

Victoza is Novo Nordisk’s once-daily injectable GLP-1 agonist and made around $3.6 billion in sales last year, making it the top-selling drug in the category.

It’s an authorized generic of Victoza. A symmetrical triangle is comprised of a descending (falling) upper trendline resistance converging with an ascending (rising) lower trendline support at ...

Krogsgaard Thomsen admitted that the U.S. is Victoza's most important potential market, but added that there could be an equal number of patients taking the drug in Europe within some 10 years ...

2024 US FDA approves Hikma's generic version of Novo's diabetes drug Victoza The U.S. Food and Drug Administration on Monday approved Hikma Pharmaceuticals' generic version of Novo Nordisk's ...

GLP-1 drug liraglutide, also known as Victoza. The drug lost patent protection last year. The agency said last week that liraglutide was still on its shortage list.